# To Evaluate Immunogenicity & Safety of GSK Bio's DTPa-HBV-IPV/Hib (Mixed Vaccine) and DTPa-IPV/Hib + HBV Vaccines

> **NCT00366366** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 150 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** Infanrix-Hexa

## Key facts

- **NCT ID:** NCT00366366
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-09
- **Primary completion:** 2002-09
- **Final completion:** 2002-09
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2016-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00366366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00366366, "To Evaluate Immunogenicity & Safety of GSK Bio's DTPa-HBV-IPV/Hib (Mixed Vaccine) and DTPa-IPV/Hib + HBV Vaccines". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00366366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*